Results 241 to 250 of about 3,245,845 (315)

Assessment of the minimal clinically important difference for the Health Assessment Questionnaire Disability Index in patients with arthralgia at risk for progression to rheumatoid arthritis. [PDF]

RMD Open
Claassen S, van Steenbergen HW, van der Helm-van Mil AHM.   +2 more
europepmc   +1 more source

[Local antirheumatic agents].

Terapevticheskii arkhiv, 1990
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Safe use of antirheumatic agents in patients with comorbidities.

Rheumatic Disease Clinics of North America, 2012
The burden of comorbid diseases is high among patients with rheumatoid arthritis (RA). These are often systemic manifestations of RA but may be chronic conditions that predate or develop post-RA diagnosis. Increased mortality in RA is predominantly from nonarticular causes.
A. Makol, K. Wright, E. Matteson
semanticscholar   +4 more sources

Reclassification of Antirheumatic Agents

Clinical Immunotherapeutics, 1994
A proposed new classification of antirheumatic therapy nominates two major categories, as follows. 1 Symptom-modifying antirheumatic drugs (SM-ARDs) improve the symptoms and clinical features of inflammatory synovitis. They can be further categorised as: (I) nonsteroidal anti-inflammatory drugs; (II) corticosteroids; and (III) slower-acting ...
Professor John Edmonds
semanticscholar   +3 more sources

Drug therapy reviews: antirheumatic agents.

American Journal of Health-System Pharmacy, 1979
The pathophysiology, symptoms and drug treatment of rheumatic disease are reviewed. Antirheumatic drugs reviewed are salicylates (including aspirin, sodium salicylate, choline salicylate, choline magnesium salicylate, salsalate), phenylpropionic acid derivatives (fenoprofen, ibuprofen, naproxen), indole derivatives (sulindac, tolmetin and indomethacin),
R. Evens
semanticscholar   +4 more sources

Cardiovascular Risk Profile of Antirheumatic Agents in Patients with Osteoarthritis and Rheumatoid Arthritis

Drugs, 2012
Several new drugs have become available for the treatment of patients with osteoarthritis and rheumatoid arthritis (RA). These agents include selective cyclooxygenase (COX)-2 inhibitors, leflunomide and anti-tumour necrosis factor (TNF)-alpha antagonists.
M. Nurmohamed, V. P. Halm, B. Dijkmans
semanticscholar   +4 more sources

The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis. [PDF]

Arthritis & Rheumatism, 1990
Harold E. Paulus
semanticscholar   +4 more sources

Articular Pharmacokinetics of Protein-Bound Antirheumatic Agents

Clinical Pharmacokinetics, 1993
By what mechanism do nonsteroidal anti-inflammatory drugs (NSAIDs) move from plasma into synovial fluid and back, and how does binding to plasma albumin in vitro relate to articular transport in vivo? To evaluate these issues, concurrent plasma and synovial fluid data of 8 different NSAIDs from 10 single-dose trials were analysed by a simple ...
P. Simkin, Maryann Wu, D. Foster
semanticscholar   +4 more sources

The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism.

Rheumatology, 1995
Increasingly, methotrexate (MTX) and sulphasalazine (SASP) are used initially for second-line therapy of rheumatoid arthritis (RA). Although SASP and MTX are commonly used, the mechanism(s) by which these drugs control the inflammation that characterizes RA have remained obscure.
B. Cronstein
semanticscholar   +4 more sources

Antirheumatic agents and leukocyte recruitment. New light on the mechanism of action of oxaceprol.

Biochemical Pharmacology, 1999
Most anti-inflammatory agents used in the treatment of joint diseases exert inhibitory effects on leukocyte infiltration. Methotrexate, a disease-modifying drug, and corticosteroids also inhibit leukocyte accumulation during inflammation. However, the mechanisms of action of these different compounds on leukocytes vary and in the case of non-steroidal ...
M. Parnham
semanticscholar   +4 more sources